



Transfers of Value methodological notes

Background:

In accordance with the Association of the British Pharmaceutical Industry (ABPI) 2019 Code of Practice Mersanta Pharma Ltd has publicly disclosed certain transfers of value made directly or indirectly to health professionals, other relevant decision makers and healthcare organisations in the UK.

Identifying categories of transfers of value:

- Consultancy
- Facilitation for example advisory boards
- Donations, grants and sponsorships
- Contributions towards the costs of meetings such as registration fees and accommodation and travel

What types of payment has Mersanta Pharma Ltd made to HCPs and HCOs during 2019?

Mersanta Pharma Ltd made two payments to healthcare professionals in 2019 for consultancy purposes with strict adherence to the code of practice. These were one-off contracts.

Transfers of Value:

We are required to document and publicly disclose certain transfers of value made to healthcare professionals, healthcare organisations and other relevant decision makers; this includes the Fee and any expenses or other transfers of value provided to them under the Engagement.

The healthcare professionals were asked to read Terms and Conditions of Engagement carefully and provide their consent by ticking the appropriate box to indicate that consent to us disclosing any transfers of value we have made to them.

Where recipients of transfers of value cannot be identified for the amount attributable to such transfers will be disclosed on an aggregate basis.

All transfers of value are disclosed in Great British Pounds (£) with no VAT.

Statement for the disclosure of 2019 data during the COVID-19 pandemic in 2020.

As part of the pharmaceutical industry's annual disclosure of transfers of value to HCPs, ORDMs and HCOs via the Disclosure UK platform and in order to ensure accuracy of the published data, the ABPI writes to all of the HCPs, ORDMs and HCOs named in companies' disclosure data ahead of its publication on Disclosure UK at the end of June. (Over 20,000 in June 2019.)

Given the unprecedented pressure on the NHS and health care professionals in responding to the COVID-19 pandemic, in April 2020 the ABPI and PMCPA agreed that it would not be appropriate for industry to write to HCPs, ORDMs or HCOs to request that disclosure data be reviewed. Doing so would add additional work for NHS professionals at this time. To avoid this, and in-line with guidance provided by the ABPI, [COMPANY]'s 2019 transfer of value data has been published on Disclosure UK in aggregate.

Commitment to transparency

The pharmaceutical industry is committed to preserving the integrity of Disclosure UK and transparency in our interactions with HCPs, ORDMs and HCOs. The ABPI continues to explore how the full disaggregated 2019 data can be submitted to Disclosure UK in line with data from previous years.

Mersanta Pharma Ltd
e-mail: info@mersantapharma.com

www.mersantapharma.com

Registered Office: 36 Mill Lane, Welwyn, England, AL6 9ET
Registered in England No. 08814187